Mechanism of Action
Cefepime is a bactericidal drug that acts by inhibition of bacterial cell wall synthesis. Cefepime has a broad spectrum of in vitro activity that encompasses a wide range of Gram-positive and Gram-negative bacteria. Within bacterial cells, the molecular targets of cefepime are the penicillin binding proteins (PBP).
Cefepime has been shown to be active against most isolates of the following microorganisms, both in vitro and in clinical infections .
Staphylococcus aureus (methicillin-susceptible isolates only)
Viridans group streptococci
Drug Label Information | Brands:
Brands of Cefepime in Kenya
C-Pime®, Zawadi Healthcare Ltd
Cefepimark®,Marksans Pharma Limited
Ceficad® , Cadila Pharmaceuticals (EA) Ltd
Ceftipime®, Renata Limited
Injpime® , Surgilinks Limited
Inno-Pime®, Innocia Lifesciences Pvt. Ltd.
Kopime®, Kopran Limited
Maxipime®, Bristol-Myers Squibb
Megapime®, Alkem Laboratories
Micropime®, Micro Labs Ltd
Necpime®, Nectar Lifesciences Limited
Pimcef®, Venus Remedies Limited
Pozineg®, Aurobindo Pharma Limited
Teico , M.J. Biopharm Pvt. Limited
Cefepime is a fourth-generation cephalosporin antibiotic. Cefepime has an extended spectrum of activity against Gram-positive and Gram-negative bacteria, with greater activity against both types of organism than third-generation agents.
INDICATIONS | DOSAGE & ADMINISTRATION
Cefepime is a cephalosporin antibacterial indicated for the treatment of the following infections caused by susceptible strains of the designated microorganisms:
1 to 2 g IV Every 8 to 12 hours for 10 days
- Empiric therapy for febrile neutropenic patients.
2 g IV Every 8hours for 7 days.
- Uncomplicated and complicated urinary tract infections (including pyelonephritis).
0.5 to 1 g IV/IM Every 12 hours for 7 to 10 days.
- Severe Uncomplicated or Complicated Urinary Tract Infections
2 g IV Every 12 hours for 10 days.
- Uncomplicated skin and skin structure infections.
2 g IV Every 12 hours 10 days.
- Complicated intra-abdominal infections (used in combination with metronidazole) in adults.
2 g IV Every 12hours 7 to 10 days.
Pediatric Patients (2 months to 16 years)
Recommended dosage in pediatric with CrCL greater than 60 mL/min. (2.2)
The usual recommended dosage in pediatric patients is 50 mg per kg per dose administered every 12 hours (every 8 hours for febrile neutropenia).
Patients with Renal Impairment: Adjust dose in patients with CrCL less than or equal to 60 mL/min.
Patients with known immediate hypersensitivity reactions to cefepime or other cephalosporins, penicillins or other beta-lactam antibacterial drugs.
WARNINGS AND PRECAUTIONS
Hypersensitivity Reactions: Cross-hypersensitivity among beta-lactam antibacterial drugs may occur in up to 10% of patients with a history of penicillin allergy. If an allergic reaction to cefepime for injection occurs, discontinue the drug.
Neurotoxicity: May occur especially in patients with renal impairment administered unadjusted doses. If neurotoxicity associated with cefepime for injection therapy occurs, discontinue the drug.
Clostridium difficile Associated Diarrhea (CDAD): Evaluate if diarrhea occurs.
The most common adverse reactions (incidence ≥ 1%) were local reactions, positive Coombs’ test, decreased phosphorous, increased ALT and AST, increased PT and PTT and rash.
At the highest dose (2 g every 8 hours), incidence of adverse reactions was ≥1% for rash, diarrhea, nausea, vomiting, pruritis, fever, and headache
Aminoglycosides: increased potential of nephrotoxicity and ototoxicity. Monitor renal function.
Diuretics: nephrotoxicity has been reported following concomitant administration of other cephalosporins with potent diuretics such as furosemide. Monitor renal function
Fever Brands of cefepime in Kenya
USE IN SPECIFIC POPULATIONS
Geriatric Use: Serious neurologic adverse reactions have occurred in geriatric patients with renal insufficiency given unadjusted doses of cefepime.
Cefepime can be found in a Pharmacy near you